ContraFect

CFRX NASDAQ
0.3974
+0.0054
+1.38%
After Hours: 0.3800 -0.0174 -4.38% 16:11 08/16 EDT
Open
0.4100
Prev Close
0.3920
High
0.4100
Low
0.3800
Volume
251.97K
Avg Vol (3M)
511.15K
52 Week High
2.629
52 Week Low
0.3550
% Turnover
0.32%
Market Cap
31.56M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers ContraFect CFRX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
MORE >

Recently

Name
Price
%Change